Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


Purpose:

Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no significant data to support the use of pulmonary vasodilators for PAH in the setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH either at rest or during exercise. The study hypothesis is that sildenafil may improve morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or exercise PAH.


Criteria:

Inclusion Criteria: - Patients with Idiopathic Pulmonary Fibrosis referred for lung transplantation at our medical center - Minimal 6 minute walk distance of 50 meters; must be able to conduct supine exercise during heart catheterization Exclusion Criteria: - Non ambulatory - Prior adverse reaction/allergy to sildenafil or other PDE-5 Inhibitors - Any other pulmonary vasodilator within one month of enrollment


NCT ID:

NCT00625079


Primary Contact:

Study Director
Rajan Saggar, MD
David Geffen School of Medicine, UCLA

Rajan Saggar, MD
Phone: 310-825-5635
Email: rsaggar@mednet.ucla.edu


Backup Contact:

Email: mdyke@mednet.ucla.edu
Michaela Dyke
Phone: 310-825-5635


Location Contact:

Los Angeles, California 90095
United States

Michaela Dyke
Phone: 310-825-5635
Email: mdyke@mednet.ucla.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 20, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.